Development of a nine‑lncRNA signature as a novel prognostic marker of estrogen receptor‑negative breast cancer

  • Authors:
    • Zhiwei Wang
    • Jie Wang
    • Lei Liu
    • Qi He
    • Min Wei
  • View Affiliations

  • Published online on: February 13, 2020     https://doi.org/10.3892/ol.2020.11391
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Long non‑coding RNAs (lncRNAs) have been demonstrated to be aberrantly expressed in several types of tumor, and dysregulated lncRNAs are suggested to play a prognostic role in breast cancer (BC). Estrogen receptor (ER) status is a prognostic factor in patients with ER‑negative BC, which is associated with poor prognosis. Thus, the present study developed a prognostic lncRNA signature specifically for ER‑negative BC, in order to predict the risk of post‑surgery relapse and improve patient prognosis. A gene expression profile containing 1,631 lncRNAs was obtained by investigating and integrating publicly available cohorts of BC. Subsequently, a nine‑lncRNA signature was developed and validated in two independent cohorts via the Cox regression model. Using the nine‑lncRNA signature, patients in the discovery cohort were divided into high‑ and low‑risk groups, with significantly different disease‑free survival [DFS; hazard ratio (HR)=2.718, 95% confidence interval (CI)=2.115‑3.494, P<0.0001]. Receiver operating characteristic curve analyses demonstrated that the area under the curve reached 0.908. Similar results were obtained in the two independent cohorts (HR=1.499, 95% CI=0.950‑2.365, P=0.04; HR=1.262, 95% CI=1.056‑1.510, P=0.01), respectively. Furthermore, the nine lncRNAs were demonstrated to play important roles in the cell invasion and metastasis of different types of tumor. The differentially expressed genes (DEGs) identified between the high‑ and low‑risk groups were consistently high in the discovery and validation cohorts. Functional analysis indicated that these DEGs, as well as genes co‑expressed with the nine lncRNAs, were involved in cancer‑associated signaling pathways, all of which provide further evidence for the predictive ability of the nine‑lncRNA signature. Overall, the present study developed a novel prognostic biomarker for ER‑negative BC.

Related Articles

Journal Cover

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Wang, Z., Wang, J., Liu, L., He, Q., & Wei, M. (1899). Development of a nine‑lncRNA signature as a novel prognostic marker of estrogen receptor‑negative breast cancer. Oncology Letters, 0, 0-0. https://doi.org/10.3892/ol.2020.11391
MLA
Wang, Z., Wang, J., Liu, L., He, Q., Wei, M."Development of a nine‑lncRNA signature as a novel prognostic marker of estrogen receptor‑negative breast cancer". Oncology Letters 0.0 (1899): 0-0.
Chicago
Wang, Z., Wang, J., Liu, L., He, Q., Wei, M."Development of a nine‑lncRNA signature as a novel prognostic marker of estrogen receptor‑negative breast cancer". Oncology Letters 0, no. 0 (1899): 0-0. https://doi.org/10.3892/ol.2020.11391